Purpose: To identify preoperative computed tomography (CT) findings associated with thymoma invasiveness before surgical resection and with clinical outcome. Methods: We retrospectively reviewed CT scans of 99 patients with thymoma surgically treated at our institution between September 1999 and April 2010. Chest CT findings documented were size, volume, and heterogeneity of primary tumor; abutment of mediastinal vessels; and presence of calcifications, lobulation, infiltration of fat surrounding tumor, adjacent pulmonary changes, adenopathy, and pleural nodularity. Results: Our study group consisted of 53 (54%) men and 46 (46%) women, age 18 -79 years (mean: 53.2 years). Masaoka pathologic stages were stage I for 10 (10%), stage II for 48 (48%), stage III for 21 (21%), and stage IV for 20 (20%). The median radiologic tumor size was 7 cm (range: 2.5-21 cm). A multivariable logistic regression model showed that primary tumors with prechemotherapy radiologic tumor size Ն7 cm (odds ratio [OR]: 3.18, 95% confidence interval [CI]: 1.16 -8.67, p ϭ 0.02), a lobulated tumor contour (OR: 8.20, 95% CI: 1.63-41.35, p ϭ 0.01), and infiltration of surrounding fat (OR: 3.76, 95% CI: 1.45-9.78, p ϭ 0.007) were more likely to have stage III or IV disease. Cox's proportional hazard model showed that the presence of pulmonary nodules on staging CT was the only imaging parameter associated with shorter progression-free survival (hazard ratio: 4.93, 95% CI: 1.60 -15.17, p ϭ 0.005) and overall survival (p ϭ 0.03). Conclusion: The primary tumor CT imaging features can differentiate between stage I/II and stage III/IV disease and, thus, help identify patients more likely to benefit from neoadjuvant therapy.
T hymomas are the most common primary neoplasm of the anterior mediastinum but account for less than 1% of malignancies in adults. 1 Their classification and staging have evolved over the past decades. The World Health Organization (WHO) classification system proposed in 1999 has been found to lack adequate reproducibility and clinical predictive value. 2 The Masaoka staging system, 3, 4 which is based on the gross and microscopic invasive properties of the tumor at surgery, is the most widely used system in clinical practice and in prospective clinical trials and has been shown to strongly correlate with prognosis. 2, 4, 5 Patients with thymomas who are obviously locally advanced at presentation typically receive neoadjuvant chemotherapy to enable effective resection, 5, 6 as complete resection, even of advanced disease, improves survival. 3, 7 Recent reports suggest that neoadjuvant therapy provides a survival advantage compared with adjuvant therapy for patients with stage III thymomas, 8 -10 but distinguishing Masaoka stage III disease from stage II disease, which does not need neoadjuvant therapy, requires postoperative pathologic examination. Thus, the postoperative Masaoka staging system and its variants cannot be used to guide decisions about neoadjuvant therapy. 4, 11 The purpose of our study was to identify preoperative computed tomography (CT) findings associated with thymoma invasiveness-Masaoka stage-and survival. Such findings could serve as a guide to distinguish patients with thymoma with locoregional invasion who may benefit from neoadjuvant therapy from patients with thymoma who will not benefit.
PATIENTS AND METHODS

Patients
For this retrospective study, we reviewed the University of Texas MD Anderson Cancer Center's computerized radiology database to identify patients referred for chest CT or positron emission tomography-CT to evaluate thymoma between September 1, 1999 , and April 5, 2010. We then reviewed these patients' computerized medical records to extract data on demographic characteristics, presence of myasthenia gravis, weight loss, and performance status (determined using the American Society of Anesthesiologists scale). We also reviewed the pathology and operative reports of each patient to determine whether they underwent resection and to determine the final diagnosis. Of the 354 patients referred for thymoma evaluation by chest CT, 255 were excluded because their preoperative chest CT scans were not available for review (n ϭ 95), their pathology slides were not available for confirmation of the diagnosis (n ϭ 67), review of the pathology report revealed they had a tumor other than thymoma (n ϭ 70), or their thymoma was not resected (n ϭ 23). Thus, the final study group composed of 99 patients who were surgically treated for thymoma and who had pathology slides and preoperative CT scans available for review.
This study was approved by the institutional review board of our cancer center, and we obtained a waiver of informed consent. In addition, our study was in compliance with Health Insurance Portability and Accountability Act regulations.
Staging
We assigned a Masaoka pathologic stage 4 to each patient by reviewing the operative report and pathology report in consultation with an experienced pathologist specializing in thymoma (C.A.M.). Briefly, stage I was assigned when the tumor was completely encapsulated; stage II when there was either microscopic invasion into the capsule (IIb) or macroscopic invasion into surrounding fat or mediastinal pleura (IIa); stage III when there was macroscopic invasion into a neighboring organ such as the pericardium, great vessels, or lung; and stage IV when there was pleural or pericardial dissemination (IVa) or lymphatic/hematogenous metastasis (IVb). WHO classification 12 for each tumor was determined (C.A.M.) from the operative specimen and was divided into atypical thymoma (WHO type B3) and thymoma (WHO type A to B2) for statistical purposes. 2, 13 Imaging Chest CT scans had been obtained using a variety of helical scanners and slice thicknesses: 1.25 mm (n ϭ 4), 2 mm (n ϭ 2), 2.50 mm (n ϭ 42), 3 mm (n ϭ 4), 3.75 mm (n ϭ 9), 5 mm (n ϭ 28), 7 mm (n ϭ 5), 7.5 mm (n ϭ 2), 8 mm (n ϭ 1), or 10 mm (n ϭ 2). Images had been reconstructed using lung and soft tissue kernels. In 87 patients, intravenous nonionic contrast medium (120 -150 ml Optiray 320; Mallinckrodt Inc., Hazelwood, MO) had been administered by an antecubital vein at a rate of 3.0 to 4.2 ml/s with a 12to 20-second delay.
The staging chest CT scans were reviewed by two chest radiologists with 12 and 11 years of experience (E.M.M. and M.A.M., respectively), while they were blinded to the clinical information. Differences in their findings were resolved by consensus. Eighty-five studies were reviewed using soft copy, and the remaining 14 were evaluated using printed images.
Imaging findings recorded for each patient were size of the primary tumor in three perpendicular diameters; estimated tumor volume; tumor homogeneity or heterogeneity; tumor lobularity or roundness; tumor calcifications; whether there was a fat plane separating the tumor from nearby blood vessels; whether tumor abutted Ն50% of circumference of vessels; infiltration of the fat abutting the tumor; and the presence of a pleural effusion, pleural nodularity, mediastinal adenopathy (defined as short axis Ͼ1 cm), pulmonary nodules, upper abdominal metastases, and bone metastases.
For reporting of tumor size, the largest of the three diameters was used. For calculation of estimated tumor volume, the three radii (r) were calculated by halving the three measured tumor diameters, and the following formula was used:
Statistical Analyses
A logistic regression model was used to estimate the probability (p) that a patient had stage III or IV thymoma. The modeling was first done in a univariable fashion; then all the covariates with a p value less than 0.10 were included in the multivariable model, and backward selection was used to obtain the final model.
A regression tree was used to assess the best cutoff size to distinguish stage I/II from stage III/IV. All parameters that were significant (p Ͻ 0.05) on multivariable analysis were then used to construct a nomogram for stage III/IV disease.
We used the method of Kaplan and Meier 14 to estimate the median overall survival and progression-free survival. Cox's 15 proportional hazards regression model was then used to test the statistical significance of several potential prognostic factors for overall survival and progression-free survival. This modeling was done in a univariable fashion. From this model, we estimated the hazard ratio (HR) for each potential prognostic factor along with a 95% confidence interval (CI). Again, all potential prognostic factors with a p value less than 0.10 from the univariable analysis were included in a saturated model, and backward elimination was used to remove factors from the model based on the likelihood ratio test in the multiple regression analysis.
The statistical software used to construct the nomogram was S-PLUS version 8.1 (TIBCO Software Inc., Palo Alto, CA) with the rpart library. The other statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Patient and Disease Characteristics
Of the 99 study patients, 53 (54%) were men and 46 (46%) were women. Their ages ranged from 18 to 79 years (mean: 53.2 years). Twenty-six (27%) had weight loss, and 10 (10%) had myasthenia gravis. The American Society of Anesthesiologists performance status score was 1 to 3 in 93 patients (93%) and 4 to 5 in 6 (6%). The Masaoka disease stage was stage I in 10 patients (10%), stage IIa in 33 patients (33%), stage IIb in 15 patients (15%), stage III in 21 patients (21%), stage IVa in 17 patients (17%), and stage IVb in three patients (3%). WHO classification was type A in 17 (17%), type AB in 9 (9%), type B1 in 24 (24%), type B2 in 27 (27%), and type B3 in 22 (22%) patients. Initial staging chest CT scans were obtained at a median of 104 days (range: 7-267 days) before surgery. For the 73 patients who had more than one CT study before surgery, the last chest CT study before surgery was obtained a median of 19 days (range: 1-73 days) before surgery. The median radiologic tumor size at presentation was 7 cm (range: 2.5-21 cm). Thirty-seven patients (37%) received cisplatin-based neoadjuvant therapy (median: 3 courses, range: 1-6 courses). Before chemotherapy, the median radiologic tumor volume was 99.73 cm 3 (range: 4.61-2507 cm 3 ). After chemotherapy, the median tumor volume was 75.45 cm 3 (range: 4.61-2069 cm 3 ). For the 62 patients who did not receive neoadjuvant chemotherapy, the median radiologic tumor volume was 46.08 cm 3 (range: 4.61-860 cm 3 ).
Radiologic Features Associated with Stage
Several radiologic features of the primary tumor showed a significant association with Masaoka stage III/IV disease. Larger tumor size, both before and after chemotherapy, was associated with stage III/IV disease, an association that was consistent (p ϭ 0.0001). Extreme sizes were particularly useful for differentiating stage III/IV from stage I/II disease. Only one (4%) of the 24 tumors less than 5 cm was stage III/IV, and only three (20%) of the 15 tumors more than 12 cm were stage I/II. A regression tree model was constructed based on the ability of maximal tumor diameter to predict stage III/IV disease. This showed the best cutoff value to be 7.15 cm. Thus, we used 7 cm as the cutoff value for maximal tumor diameter for further analyses and nomogram construction. Univariable analysis also showed that stage III/IV disease was associated with primary tumors that were lobulated (p ϭ 0.001), were heterogeneous (p ϭ 0.0004), had calcifications within them (p ϭ 0.04), infiltrated surrounding mediastinal fat (p ϭ 0.0002), abutted Ն50% of circumference of vessels (p ϭ 0.0007), or resulted in adjacent lung changes (p ϭ 0.0001). Pleural effusion (p ϭ 0.01), pleural nodularity (p ϭ 0.001), WHO type B3 (p ϭ 0.02), and younger age (p ϭ 0.04) were also associated with stage III/IV disease ( Table 1 ; Figures 1 and 2) .
Multivariable logistic regression model of the primary tumor variables showed that only tumor size, infiltration of surrounding fat, and lobularity of the tumor were associated with the risk of having stage III/IV thymoma. Patients with Ն7 cm tumors before chemotherapy were more likely to have stage III/IV disease than patients with less than 7 cm tumors (odds ratio [OR]: 3.18, 95% CI: 1.16 -8.67, p ϭ 0.02). Patients with infiltration of surrounding fat were more likely to develop stage III/IV thymoma than patients without infiltration of surrounding fat (OR: 3.76, 95% CI: 1.45-9.78, p ϭ 0.007); patients with a lobulated tumor were more likely to have higher stage disease than patients with a round tumor (OR: 8.20, 95% CI: 1.63-41.35, p ϭ 0.01).
A clinical nomogram was then constructed based on tumor size at presentation (Ն7 cm or Ͻ7 cm), presence of a lobulated tumor, and infiltration of fat surrounding the tumor (Figure 3 ). Internal validation using the bootstrap method with 200 repetitions yielded a bias-corrected concordance index of 0.795 with an optimism of 0.009. Receiver operating characteristic curve analysis demonstrated that the nomogram was accurate in predicting stage III/IV disease (area under the curve: 80%) ( Figure 4 ).
To overcome possible downstaging of the 37 patients who received neoadjuvant therapy, as 18 (48%) were found to have stage I/II disease, univariable analysis of those who did not receive neoadjuvant therapy (n ϭ 62) showed that stage III/IV disease remained associated with primary tumors that were Ն7 cm (p ϭ 0.001), lobulated (p ϭ 0.01), heterogenous (p ϭ 0.03), had calcifications (p ϭ 0.04), were associated with infiltrated surrounding mediastinal fat (p ϭ 0.007), or resulted in adjacent lung changes (p ϭ 0.001).
When evaluating the imaging parameters that may signify distant metastatic disease (stage IVa or IVb), univariate analysis showed that pleural nodularity (p ϭ 0.001), pleural effusion (p ϭ 0.01), and mediastinal lymphadenopathy (p ϭ 0.03) were associated with stage III/IV disease but not pulmonary nodules (p ϭ 0.06). Multivariable analysis of these distant disease parameters in conjunction with the primary tumor parameters showed that only pleural nodularity (p ϭ 0.002) and tumor Ն7 cm (p ϭ 0.04) remained significant.
Because all patients with pleural nodularity (n ϭ 22) had stage III/IV disease, to assess which CT parameters of the primary tumor signify advanced disease when the pleura appears normal, we then studied the 77 patients without pleural nodularity. In patients presenting with a normal appearing pleura, univariable analysis showed that CT factors associated with stage III were tumor size Ն7 cm (p ϭ 0.03), primary tumors that are lobulated (p ϭ 0.04), heterogeneous (p ϭ 0.01), have calcifications within them (p ϭ 0.04), infiltrate surrounding mediastinal fat (p ϭ 0.02), abut Ն 50% of circumference of vessels (p ϭ 0.02), or result in adjacent lung changes (p ϭ 0.02). Nevertheless, multivariable analysis showed that in this group of patients, only infiltration of the surrounding fat (OR: 3.59; 95% CI: 1.02-12.60; p ϭ 0.04) and tumor heterogeneity (OR: 0.14; 95% CI: 0.03-0.67; p ϭ 0.01) remained associated with stage III disease.
Tumor Classification Associated with Radiologic Features and Stage
WHO type B3 was associated with advanced disease (stage III/IV) (p ϭ 0.02). Of the imaging parameters assessed (Table 1) , the only imaging parameter that WHO type B3 tumors were associated with was large tumor size (p ϭ 0.02), as 17 of the 22 (77%) patients with type B3 tumors had a primary tumor Ն7 cm.
Survival
Patients were followed up for a mean of 40 months (range: 3.1-131.7 months) after CT presentation. Within this follow-up period, 28 patients had progression of disease and 10 died.
Cox's proportional hazard model showed that the presence of pulmonary nodules (p ϭ 0.0002), pulmonary changes adjacent to the primary tumor (p ϭ 0.006), mediastinal adenopathy (p ϭ 0.0005), lobularity of the tumor (p ϭ 0.02), tumor abutting Ն50% of mediastinal vessels (p ϭ 0.02), The only imaging variable associated with worse overall survival in Cox's proportional hazard model was the presence of pulmonary nodules (p ϭ 0.03). Clinical patient variables, other imaging variables, tumor type, and stage were not associated with overall survival. A Ն50% nomogram probability of having stage III/IV disease was associated with a shorter progression-free survival (p ϭ 0.005) ( Figure 5 ) but was not associated with overall survival (p ϭ 0.66).
DISCUSSION
We have found that the CT appearance of the primary tumor is useful in distinguishing stage I or II thymomas from stage III or IV disease. The preoperative CT features of larger tumor size, lobulated tumor, and infiltration of fat surrounding the tumor suggest a high probability of Masaoka stage III or IV disease. When a patient with normal appearing pleura presents, tumor heterogeneity and infiltration of the surrounding fat are most associated with stage III disease. Contrast-enhanced chest computed tomography (CT) scan demonstrates an 8.5-cm anterior mediastinal mass (arrow) that is lobulated, is poorly demarcated, does not infiltrate the surrounding fat, and abuts Ͻ50% of the circumference of the ascending aorta (A). At surgery, the tumor was found to invade the pleura, lung parenchyma, and innominate vein. P, left pulmonary artery.
FIGURE 3.
Nomogram to predict stage III/IV thymoma using computed tomography (CT) findings at presentation. The nomogram consists of six rows. Row 1 (points row) is the point assignment for each variable. Rows 2 to 4 correspond to the variables included in the model. For an individual patient, each variable in rows 2 to 4 is assigned a point value, which is determined by drawing a vertical line from the appropriate position on the variable row to the points row. The assigned points for all three variables are added, and the total is marked on row 5 (shaded row called: total points). Then, the probability of having stage III/IV disease is calculated by drawing a vertical line from the appropriate position on the total points row to the row 6, which shows the probability of stage III or IV disease. Thus, for a patient with a lobular, larger than 7 cm tumor, which infiltrates the surrounding fat, the points added would be 100, 55, and 63 points, respectively, which adds to 218 total points or a 75% probability of having stage III/IV disease. The concordance index of this nomogram is 0.804. After internal validation using 200 bootstrap samples, the bias-corrected concordance index was 0.795 with an optimism of 0.009. Using this point system, total points Ն164 predict a Ն50% probability of having stage III/IV disease.
Previous studies have assessed whether thymoma size at surgery is associated with long-term survival. The smaller studies did not find a correlation between tumor size and overall survival, 7, 16 whereas the larger studies found that larger tumors were more likely to recur. 3, 17, 18 In our study, larger tumors were not associated with overall or progressionfree survival.
The few prior studies that focused on the CT appearance of thymoma found that CT could not distinguish between the different WHO histologic subtypes of thymomas. 19 -22 This may be due to inherent problems with the WHO classification system for thymoma, rather than due to the imaging itself. 2 The interobserver and intraobserver reproducibility for interpreting pathologists can be poor with the WHO system. 23 To complicate matters, thymomas are characterized by morphologic heterogeneity. Thus, several WHO subtypes often coexist in the same tumor, making it difficult to assign a tumor classification, particularly on the basis of a preoperative needle biopsy specimen that may not have sampled the areas of the tumor with the predominant subtype. 2 By using a modified WHO system, 2,13 we were able to show a correlation of tumor size with histologic classification. In addition, the WHO classification system cannot be used to predict clinical outcome [23] [24] [25] but with the modified system was found to be associated with progression-free survival.
We chose to compare our CT findings to stage determined using the Masaoka staging system, which has been shown to be an independent predictor of recurrence and long-term survival. 3, 18, 26 To our knowledge, only two previous studies examined the relationship of the CT appearance of thymoma to the Masaoka stage. 27,28a In those studies, the authors examined whether CT appearance could distinguish stage I disease from higher stages. The researchers were able to identify some CT findings that were more common in invasive thymomas, such as lobulated contours, irregular contours, and larger tumor size; but these features were also seen-though generally to a lesser degree-in a substantial number of the encapsulated thymomas they assessed. In contrast, we assessed whether CT could distinguish stage I/II disease from stage III/IV.
There have been no prospective randomized controlled trials providing level I evidence on the best therapeutic approach to thymoma. There is consensus that stage I thymomas can be treated with surgery alone, with no adjuvant therapy, because completely resected stage I thymomas have only a 0.9% overall recurrence risk and are associated with a 5-year overall survival rate of 100%. 26, 28, 29 At present, however, there is individual and institutional variation in the sequencing of treatment for higher stages of thymoma (stages II-IV). For completely resected stage II disease, radiation and/or chemotherapy given as neoadjuvant therapy and/or adjuvant therapy are not recommended. 26, 28 Nevertheless, despite the fact that radiation therapy after complete resection of stage II disease has not been shown to make a difference in disease-free or overall survival, 30,31 some institutions do administer radiation therapy because of older data showing that stage II disease has a higher risk of local recurrence than stage I disease. 32 Furthermore, some patients with stage II disease may receive neoadjuvant therapy because imaging techniques have historically not been able to reliably detect vessel involvement and thus distinguish stage II from stage III disease. Unlike for stage II disease, neoadjuvant therapy for stage III disease has been shown to be beneficial and is recommended. 8 -10,26,28,33 Thus, a means of preoperatively identifying those patients who can benefit from neoadjuvant therapy-those with stage III or IV disease-is necessary. The nomogram proposed in our study creates a simple way to generate an individual's probability of having stage III/IV disease. With internal validation of the nomogram performed using 200 bootstrap samples, we obtained a bias-corrected concordance index of 0.795 with an optimism of 0.009, suggesting clinical accuracy of the nomogram.
Although further validation is needed, we are hopeful that our nomogram will enable patients who will not benefit from neoadjuvant therapy-those with stage I/II disease-to be spared the potential harm that accompanies it. Patients with thymoma have high 5-and 10-year overall survival rates, so the likelihood of suffering long-term adverse effects from unnecessary radiation and/or chemotherapy cannot be overlooked. 34 The potential complications from these therapies include cardiac damage and secondary malignancies. Even with the newer radiation techniques (such as threedimensional conformal radiation, intensity-modulated radiation therapy, and proton therapy) currently used to decrease the radiation dose to surrounding normal tissues, irradiation of the heart cannot always be avoided as thymomas often abut the heart. Patients whose hearts are exposed to radiation are known to suffer from cardiomyopathy and accelerated coronary artery disease, and these effects can be increased by the addition of chemotherapy. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Neoadjuvant chemotherapy can be cardiotoxic as well and can lead to cardiomyopathy. 46 Secondary malignancies are seen in up to 28% of long-term thymoma survivors. 5 Although it is not clear whether this is due to treatment or to other thymoma-associated factors, secondary solid tumors in thymoma survivors occur most often within the radiation field. 47 Our study has the usual limitations of a retrospective study. In addition, the population size is rather small but reflects the rarity of thymoma. Although some patients received neoadjuvant therapy before surgical staging, which affected tumor size in some, the tumor size association with the risk of having stage III/IV thymoma persisted. The fact that only pulmonary nodules were associated with poor overall survival may be due to the fact that only 10 patients died in our study; the power to detect meaningful associations between any factor and overall survival was therefore fairly low. The relatively short follow-up period may also have affected our ability to detect overall survival associations. Even patients with locally aggressive thymoma (stage III) have up to a 60% 10-year overall survival rate. 26 To overcome the issue of the rarity of this disease, the International Thymic Malignancy Interest Group was recently formed, through which we plan to validate our nomogram in a multiinstitutional study. We hope that this will provide a deeper understanding of thymoma and lead to evidence-based imaging and treatment of this disease.
In conclusion, CT imaging of thymoma may be useful to distinguish between stage I/II and stage III/IV thymoma. Although further validation is needed, we hope our findings will ultimately enable physicians to determine at presentation which patients with thymoma will benefit from neoadjuvant therapy and which will not.
